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Abstract: Among 469 women with a diagnosis of HIV in
pregnancy, 74 (15.8%) presented with less than 200 CD4 cells per
cubic millimeter. The only variable signiﬁcantly associated with this
occurrence was African origin (odds ratio: 2.22, 95% conﬁdence
intervals: 1.32 to 3.75, P = 0.003). Four women with low CD4
(5.6%), compared with none with higher CD4 counts, had severe
AIDS-deﬁning conditions (P , 0.001) during pregnancy or soon
after delivery, and one transmitted HIV to the newborn. Early
preterm delivery (,32 weeks) was signiﬁcantly more frequent with
low CD4 (6.2% vs. 1.4%, P = 0.015). An earlier access to HIV
testing, particularly among immigrants of African origin, can prevent
severe HIV-related morbidity.
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INTRODUCTION
Despite the signiﬁcant improvements achieved in the
treatment and prognosis of HIV infection and the widespread
efforts aimed at increasing HIV testing among sexually active
individuals, late diagnosis of HIV is still frequent in several
Western countries, with signiﬁcant clinical and therapeutic
challenges, additional costs, and increased morbidity and
mortality.1–3 Several studies have evaluated the prevalence
and correlates of a late diagnosis in the course of HIV
infection, showing a variety of potential predictors, that
include male gender, younger age, foreign nationality or
migrant status, history of drug use, transmission through
heterosexual contacts, lower level of education, and poorer
clinical status.4–8
This issue, however, has rarely been addressed in
pregnant women,9,10 although they represent a particularly
vulnerable population, characterized by speciﬁc clinical and
therapeutic requirements and by an additional risk of
pregnancy-related complications.11 Given the clinical rele-
vance of this issue, we used data from a national study of
pregnant women with HIV to analyze the proportion of newly
diagnosed pregnant women with advanced disease, the
determinants of this occurrence, and its impact on maternal
and neonatal outcomes.
METHODS
Data from the National Program on Surveillance on
Antiretroviral Treatment in Pregnancy were used.12 This is
a national observational study of pregnant women with HIV
established in Italy in 2001, reﬂecting current clinical care.
Only HIV-positive pregnant women are included, and no
speciﬁc guidance is given in terms of treatment of HIV
infection or prophylaxis for mother-to-child transmission,
which is decided by the treating physician. Laboratory and
clinical data are collected from hospital records of Obstetrics,
Infectious Diseases, and Pediatrics departments, following the
women’s consent. Information and measurements are col-
lected at routine visits performed during pregnancy (with no
restrictions in gestational age at entry into prenatal care), at
delivery, during postpartum, and during a follow-up of
mothers and newborns for up to 18 months. For the present
analysis, we considered all pregnancies with known dates of
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HIV diagnosis and of last menstrual period and compared
baseline characteristics and clinical outcomes according to the
presence of advanced HIV disease. Time of diagnosis was
categorized as “in pregnancy” or “before pregnancy” using
the date of last menstrual period as threshold, and advanced
disease was deﬁned by a CD4 cell count below 200/mm3 or
the presence of an AIDS-deﬁning clinical condition. Major
birth defects were deﬁned according to the Antiretroviral
Pregnancy Registry criteria,13 and gender- and gestational
age–adjusted Z scores for birth weight were calculated
according to national reference standards.14 Preterm and early
preterm delivery were deﬁned as delivery before 37 and 32
completed weeks of gestation, respectively, and low and
very low birth weight by values below 2500 and 1500 g,
respectively. Cesarean section was considered elective if
performed before the rupture of membranes and the onset
of labor and nonelective if performed after the rupture of
membranes, onset of labor, or both. Quantitative data were
compared by Mann–Whitney U test, and the temporal
trends were analyzed using the x2 test for trend. Contin-
gency tables and the x2 test were used to compare
qualitative variables and to estimate odds ratios and 95%
conﬁdence intervals for the relevant outcomes. P values
below 0.05 were considered signiﬁcant. All analyses were
performed using the SPSS software, version 22.0 (IBM,
Somers, NY).
RESULTS
As of October 8, 2014, the study database contained
2478 pregnancies with known date of HIV diagnosis. Rate of
HIV diagnosis in pregnancy across the entire study period
(2001–2014) was 23.8%, with no signiﬁcant time trend
observed (P = 0.585, x2 for trend). Among the 591 cases with
HIV diagnosis in pregnancy, 469 (79.3%) had available
information on CD4 count and/or HIV disease stage and were
further analyzed. The rate of advanced disease among new
HIV diagnoses in pregnancy was 15.8% (74/469), with no
major temporal changes during the observation period (2001–
2014: P = 0.581, x2 for trend). In 4 cases with CD4 cell count
below 200/mm3 (5.6%), an AIDS-deﬁning clinical condition
was diagnosed either in pregnancy or soon after delivery.
These conditions were represented by 2 cases of neurotox-
oplasmosis, one case of large B-cell non-Hodgkin lymphoma
and one case who, at the same time, had esophageal candidiasis
and Pneumocystis pneumonia. No cases of AIDS-deﬁning
events were observed among women diagnosed with HIV
in pregnancy with more than 200 CD4 cells per cubic
millimeter (P , 0.001).
Among women with a diagnosis of HIV in pregnancy,
the only variable signiﬁcantly associated with advanced disease
was African origin (odds ratio: 2.22, 95% conﬁdence intervals:
1.32 to 3.75, P = 0.003), whereas there was no signiﬁcant
association with age (P = 0.395), parity (P = 0.642), route of
transmission (P = 0.148), and history of sexually transmitted
diseases (P = 0.469).
The main maternal and neonatal outcomes are reported
in Table 1. The 2 groups of newly diagnosed pregnant women
with and without low CD4 had similar rates of undetectable
HIV RNA at third trimester, mode of delivery, preterm
delivery, and pregnancy complications. The infants from the
2 groups of mothers did not differ in birth weight (2950 vs.
2825 g, P = 0.971), Z score for birth weight (20.22 vs.
20.20, P = 0.989), and in rates of low birth weight, major
birth defects, and HIV transmission (Table 1). In addition to
the above-reported signiﬁcantly higher risk of being diag-
nosed with severe AIDS-deﬁning clinical conditions, women
with advanced disease also had a signiﬁcantly higher rate of
early preterm delivery (,32 weeks: 6.2% vs. 1.4%, P =
0.015), with a trend for more frequent occurrence of very low
birth weight (,1500 g: 6.8% vs. 2.1%, P = 0.093).
DISCUSSION
This study explored late presentation with advanced
disease in pregnant women with HIV, providing new
information on a previously poorly studied population:
a recent review from Siedner referring to adults diagnosed
with HIV in sub-Saharan countries found few studies in
pregnant women and provided no information on maternal
and infant outcomes.9 A more population-speciﬁc, although
less recent, study conducted in Brazil between 2007 and 2009
found that the prevalence of late presentation (deﬁned by less
than 350 CD4 cells per cubic millimeter) was less than half in
pregnant women (21.1%) compared with both nonpregnant
women (56.0%) and men (55.4%).10 The prevalence that we
observed among pregnant women (15.8%), considering the
lower CD4 threshold adopted (,200/mm3), can be consid-
ered as consistent with the above ﬁndings. The data collected
also indirectly conﬁrm, compared with available national
data, that in women diagnosed with HIV in pregnancy,
presentation with low CD4 is less frequent compared with the
general population: in the national study by Camoni et al5,
advanced disease at diagnosis involved 37.8% of all new HIV
diagnoses reported in Italy during 2010–2011.
Despite the lower prevalence, the clinical impact of
this condition was relevant because 4 women in this
subgroup were diagnosed during pregnancy or soon after
delivery with severe AIDS-deﬁning conditions that
required speciﬁc treatment. One of such cases was also
associated with mother-to-child transmission of HIV.
Importantly, among women diagnosed with HIV in preg-
nancy, only those with less than 200 CD4 cells per cubic
millimeter seemed to be at risk of developing AIDS-
deﬁning conditions in pregnancy. Women with presentation
in advanced disease had also a higher rate of early preterm
delivery (,32 weeks), a condition which is known to be
associated with signiﬁcant infant morbidity because of
prematurity-related complications.
The only variable signiﬁcantly associated with pre-
sentation in advanced HIV disease was African provenance.
This is consistent with other studies on late diagnosis in the
general population.1,2,15 Other studies have shown that
pregnant women of African ethnicity are also signiﬁcantly
more likely to book late for antenatal care,16 a condition that
increases the risk of adverse maternal and infant outcomes,
including HIV transmission.17 Taken together, these obser-
vations strongly underline the need to promote an earlier
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access to HIV testing and care among immigrants, particu-
larly of African origin, removing any potential restriction
that may delay access to health care.
In term of strengths and weaknesses, the determinants
and consequences of a presentation to antenatal care with
undiagnosed advanced HIV disease in a national cohort of
pregnant women have been described for the ﬁrst time. The
new information provided can be relevant for prevention
strategies targeted to populations at risk and for calculating
the costs of the maternal and neonatal morbidity (AIDS events
and HIV transmission) associated with late presentation.
The main limitation of this study is the relatively small
number of women with advanced disease, which may have
precluded the possibility to detect other relevant associations.
This is, however, not the consequence of a limited sample
size but rather of the fact that presentation with advanced
disease, although associated with clinically signiﬁcant dis-
ease, is fortunately relatively rare among pregnant women
compared with the general population. It is important to note
that the number of women presenting with advanced disease
was adequate to detect signiﬁcant outcome differences with
women with less advanced CD4 deterioration. As for other
observational cohorts, we also cannot rule out some inherent
sources of bias, such as missing data, participation of selected
centers, or selective case reporting.
In conclusion, this study identiﬁed African origin as
a determinant of presentation in advanced disease and showed
that this occurrence is associated with clinically important
adverse outcomes; efforts and interventions are still needed to
promote an earlier access to HIV testing that can be
signiﬁcantly effective in preventing maternal clinical pro-
gression and infection of the newborn with HIV.
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